Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 947 participants.

Also called NCT02545842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 947 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02545842
Other papers using this trial's data
  • Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis Advances in therapy, 2020-09 DOI, PubMed 32671687
  • Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III) Advances in therapy, 2022-01 DOI, PubMed 34757600
  • Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study Advances in therapy, 2022-06 DOI, PubMed 35430674, PMC9123059 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02545842. Randomized; no masking; primary purpose treatment. Start 2015-09-07 (registry gives no type); primary completion 2018-04-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02545842
Content hash
b8f344130df30acadc14fc2402fd88700093826d7a7697f46a6b0a40c83836f3